Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits.

about

Apo A-I (Apolipoprotein A-I) Vascular Gene Therapy Provides Durable Protection Against Atherosclerosis in Hyperlipidemic Rabbits.

Item

http://www.wikidata.org/entity/Q45874236

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Apo A-I (Apolipoprotein A-I) V ...... sis in Hyperlipidemic Rabbits.

@en

Apo A-I

@nl

type

Item

label

Apo A-I (Apolipoprotein A-I) V ...... sis in Hyperlipidemic Rabbits.

@en

Apo A-I

@nl

prefLabel

Apo A-I (Apolipoprotein A-I) V ...... sis in Hyperlipidemic Rabbits.

@en

Apo A-I

@nl

P1476

Apo A-I (Apolipoprotein A-I) V ...... sis in Hyperlipidemic Rabbits.

@en

P2093

Alexis Stamatikos

http://www.w3.org/2001/XMLSchema#string

Bradley K Wacker

http://www.w3.org/2001/XMLSchema#string

David A Dichek

http://www.w3.org/2001/XMLSchema#string

Lianxiang Bi

http://www.w3.org/2001/XMLSchema#string

Nagadhara Dronadula

http://www.w3.org/2001/XMLSchema#string

P2860

The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway

ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

Efficacy of gene therapy for X-linked severe combined immunodeficiency

Comparative Effects of Diet-Induced Lipid Lowering Versus Lipid Lowering Along With Apo A-I Milano Gene Therapy on Regression of Atherosclerosis

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

Effects of torcetrapib in patients at high risk for coronary events

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

P31

scholarly article

P356

10.1161/ATVBAHA.117.309565

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29122817

http://www.w3.org/2001/XMLSchema#string

P921

hyperlipidemia

gene therapy

P932

5746433

http://www.w3.org/2001/XMLSchema#string